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Abstract
Although gemcitabine has been accepted as the first-
line chemotherapeutic reagent for advanced pancrea-
tic cancer, improvement of response rate and survival
is not sufficient and patients often develop resistance.
We hypothesized that the inhibition of phosphoryla-
tion of epidermal growth factor receptor (EGFR) and
vascular endothelial growth factor receptor (VEGFR)
on tumor cells and tumor-associated endothelial
cells, combined with gemcitabine, would overcome
the resistance to gemcitabine in orthotopic pancreatic
tumor animal model. L3.6pl, human pancreatic cancer
cells growing in the pancreas, and tumor-associated
endothelial cells in microorgan environment highly ex-
pressed phosphorylated EGFR, VEGFR, and Akt, which
regulates antiapoptotic mechanism. Oral administra-
tion of AEE788 (dual tyrosine kinase inhibitor against
EGFR and VEGFR) inhibited the phosphorylation of
EGFR, VEGFR, and Akt on tumor-associated endothelial
cells as well as tumor cells. Although intraperitoneal
(i.p.) injection of gemcitabine showed limited inhibitory
effect on tumor growth, combination with AEE788 and
gemcitabine produced nearly 95% inhibition of tumor
growth in parallel with a high level of apoptosis on
tumor cells and tumor-associated endothelial cells,
and decreased microvascular density and prolifera-
tion rate. Collectively, these data indicate that dual
inhibition of phosphorylation of EGFR and VEGFR, in
combination with gemcitabine, produces apoptosis
of tumor-associated endothelial cells and significantly
suppresses human pancreatic cancer in nude mice.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer
death in the United States with 28,000 new cases diagnosed
annually [1]. The difficulty in detecting pancreatic cancer at
an early stage, the aggressive nature of the disease, and
the lack of effective therapy are all responsible for the high
mortality from this disease [2], a 1-year survival rate of 18%, and
a 5-year survival rate of less than 3% [1,3]. Systemic therapy
with gemcitabine (2V,2V-difluorodeoxycytidine), a deoxycytidine
analogue most recently used against pancreatic cancer, has not
increased the median survival of patients beyond 6 months and
often leads to resistance [3,4]. Clearly, an effective treatment for
this devastating disease is urgently needed.
The molecular biology of pancreatic cancer may present
therapeutic opportunities. Recent advances have identified a
number of biologic and genetic abnormalities, including over-
expression of such growth factors as epidermal growth factor
(EGF), vascular endothelial growth factor (VEGF), insulin-like
growth factor (IGF), and basic fibroblast growth factor (bFGF)
and their receptors [5–8]. The binding of ligands to their
receptors has been shown to enhance the malignant pheno-
type of cancer by activating downstream protein kinase cas-
cades, such as the one involving PI3K/Akt, MAPK, and nuclear
factor-kappa B (NF-nB) that controls cell proliferation, angio-
genesis, chemoresistance, and apoptosis [9–14].
The increase in VEGF production seen in many cancers
leads to greater microvascular density (MVD) and is associated
with a poor prognosis [15]. This growth factor acts not only as a
mitogenic and permeability factor but also as an antiapoptotic
survival factor for vascular endothelial cells [16,17]. A vascular
endothelial growth factor receptor (VEGFR) tyrosine kinase
inhibitor and an antibody against VEGF have been shown to
inhibit angiogenesis and the progressive growth of tumors
in animals. For example, bevacizumab (Avastin; Genentech,
Inc., South San Francisco, CA) is a recombinant humanized
Abbreviations: EGFR, epidermal growth factor receptor; HBSS, Hanks’ balanced salt solution;
VEGFR, vascular endothelial growth factor receptor; MVD, microvascular density; PBS,
phosphate-buffered saline; PCNA, proliferating cell nuclear antigen
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monoclonal antibody against VEGF that inhibits its binding
to VEGFR [18]. In stage IV pancreatic cancer patients, be-
vacizumab, combined with gemcitabine, produced a 21%
partial response rate and 45% of the patients had stable
disease. The increase in median survival to 9 months was
also encouraging [19]. The overexpression of EGF and
epidermal growth factor receptor (EGFR) correlates with
development of cancer metastasis and resistance to chemo-
therapy [14,20–22]. In a phase II clinical trial, the adminis-
tration of cetuximab (IMCC225, Erbitux; ImClone, New York,
NY), a monoclonal antibody targeting EGFR [23], in com-
bination with gemcitabine, produced 12% partial response
and stable disease in 63% of the advanced pancreatic
cancer patients [24].
Collectively, these data imply that dual inhibition of EGFR
and VEGFR signaling pathways could be useful in the
treatment of pancreatic cancer [25,26]. One possible inhib-
itor is AEE788, a recently described specific tyrosine kinase
inhibitor of EGFR and VEGFR tyrosine kinases [27]. To
establish this inhibitor’s potential, we determined whether
AEE788, administered alone or in combination with gemci-
tabine, can inhibit the progressive growth and spread of
human pancreatic cancer cells implanted into the pancreas
of nude mice.
Materials and Methods
Pancreatic Cancer Cell Line and Culture Conditions
The human pancreatic cancer cell line, L3.6pl [26], was
maintained in minimal essential medium supplemented
with 10% fetal bovine serum (FBS), sodium pyruvate, non-
essential amino acids, L-glutamine, a two-fold vitamin solution
(Life Technologies, Grand Island, NY), and a penicillin–
streptomycin mixture (Flow Laboratories, Rockville, MD).
The cultures were free of mycoplasma and the following
pathogenic murine viruses: reovirus type 3, pneumonia virus,
K virus, Theiler’s encephalitis virus, Sendai virus, minute
virus, mouse adenovirus, mouse hepatitis virus, lymphocytic
choriomeningitis virus, ectromelia virus, and lactate dehydro-
genase virus (assayed by Science Applications International
Corp., Frederick, MD).
Nucleotide Sequence Analysis of EGFR in Pancreatic
Cancer L3.6pl Cell Line
We analyzed for DNA sequence variations in exons 18,
19, and 21 of the kinase domain of EGFR shown to have
mutations in patients who responded to therapy [28]. DNA
was extracted from log phase cultures of L3.6pl cells using
the DNeasy Tissue Kit No. 69504 (Qiagen, Inc., Valencia,
CA). Mutational analysis was performed by the Molecular
Diagnostic Laboratory of the M. D. Anderson Cancer Center
(Houston, TX). Nested PCR products of exons 18, 19, and
21, obtained using primers previously described [28], were
directly sequenced in sense and antisense directions. All
sequences were screened for the presence of mutations both
manually and using the SeqScape software and confirmed
by two independent PCR amplifications. The results clearly
indicate that the L3.6pl cells contain a wild-type EGFR.
Reagents
AEE788 (Novartis Pharma, Basel, Switzerland), 7H-
pyrrolo[2,3-d]pyrimidine lead scaffold, is an ATP-competitive
dual EGFR and VEGFR tyrosine kinase family inhibitor [27].
For in vitro use, AEE788 was dissolved in dimethyl sulfoxide
(Sigma-Aldrich Corp., St. Louis, MO) to a concentration of
20 mM and further diluted to an appropriate final concen-
tration in RPMI 1640 medium with 10% FBS. Dimethyl sulf-
oxide in the final solution did not exceed 0.1% vol/vol.
For in vivo administration (oral), AEE788 was dissolved in
N-methylpyrrolidone and polyethylene glycol 300 1:9 (vol/
vol). The AEE788 solution was prepared just before it was
administered to the mice. Paclitaxel (Mead Johnson, Prince-
ton, NJ) was diluted 1:6 in phosphate-buffered saline (PBS)
for intraperitoneal (i.p.) injections.
The following primary antibodies were purchased from
their respective manufacturers: rabbit anti–p-VEGFR 2/3
(Flk-1) (Oncogene, Boston, MA); rabbit anti–human VEGF
(SC152); rabbit anti–human mouse, rat VEGFR (Flk-1)
(C1158) (Santa Cruz Biotechnology, Santa Cruz, CA); rabbit
anti–human p-EGFR (Tyr 1173) (Biosource, Camarillo, CA);
rabbit anti–human EGF (SC275) and rabbit anti–human
EGFR (SC03) for paraffin samples (Santa Cruz Biotechnol-
ogy); rabbit anti–human EGFR for frozen samples (Zymed,
San Francisco, CA); rat anti–mouse CD31 (BD PharMingen,
San Diego, CA); mouse anti–proliferating cell nuclear anti-
gen (PCNA) clone PC 10 (Dako A/S, Copenhagen, Den-
mark); rabbit anti–mouse, human, rat phospho-Akt (Ser 473)
and rabbit anti –human phosphorylated MAPK/ERK1/2
(phospho-p44/42 MAP [ERK1/2] kinase antibody) (Cell Sig-
naling, Beverly, MA); and donkey anti– rabbit IGG-HRP
(Santa Cruz Biotechnology). The following secondary anti-
bodies were used for colorimetric immunohistochemistry:
peroxidase-conjugated goat antirabbit IgG; F(abV)2 (Jackson
ImmunoResearch Laboratories, West Grove, PA); biotiny-
lated goat antirabbit (Biocare Medical, Walnut Creek, CA);
streptavidin horseradish peroxidase (Dako A/S); rat anti–
mouse IgG2a horseradish peroxidase (Serotec; Harlan Bio-
products for Science, Indianapolis, IN); and goat anti–rat
horseradish peroxidase (Jackson ImmunoResearch Labora-
tories). We obtained the fluorescent secondary antibodies
goat anti–rabbit Alexa 488 and goat anti–rat Alexa 594 from
Molecular Probes (Eugene, OR). Terminal deoxynucleotidyl
transferase–mediated nick end labeling (TUNEL) staining
was performed using a commercial apoptosis detection kit
(Promega, Madison, WI).
Animals and Orthotopic Implantation of Tumor Cells
Male athymic nude mice (NCI-nu) were purchased from
the Animal Production Area of the National Cancer Insti-
tute Frederick Cancer Research and Development Center
(Frederick, MD). The mice were housed under specific
pathogen-free conditions in facilities approved by the Ameri-
can Association for Accreditation of Laboratory Animal Care
and in accordance with current regulations and standards
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of the U.S. Department of Agriculture, U.S. Department of
Health and Human Services, and the National Institutes of
Health. The mice were used in accordance with institutional
guidelines when they were 8 to 12 weeks old.
To produce pancreatic tumors, we harvested L3.6pl cells
from subconfluent cultures by a brief exposure to 0.25%
trypsin and 0.02% EDTA. Trypsinization was stopped with
medium containing 10% FBS, and the cells were washed
once in serum-free medium and resuspended in Hanks’
balanced salt solution (HBSS). Only suspensions consisting
of single cells with greater than 90% viability were used
for the injections. One million cells suspended in 50 m
`
l of
HBSS were injected into the pancreas of nude mice as
described previously [26,29].
Treatment of Nude Mice with Established Orthotopic
Human Pancreatic Cancer
Fourteen days after the injection of L3.6pl tumor cells
into the pancreas, all mice were randomized to one of the
following four treatment groups (n = 10): (a) oral gavage
three times per week with water diluted 1:20 with DMSO–
0.5% Tween 80 (diluent), and two i.p. injections per week of
PBS (control group); (b) oral gavage of diluent three times
per week, and two i.p. injections per week of gemcitabine
(50 mg/kg); (c) oral gavage of AEE788 (50 mg/kg) three
times per week, and two i.p. injections per week of PBS; and
(d) oral gavage of AEE788 (50 mg/kg) three times per week,
and two i.p. injections per week of gemcitabine (50 mg/kg).
The treatment continued for 5 weeks, at which time the mice
were killed and necropsied.
Necropsy Procedure and Histologic Studies
Before necropsy, mice were weighed, and tumors were
then excised and weighed. For histology and immunohisto-
chemical (IHC) analyses, one part of the tumor tissue was
fixed in formalin and embedded in paraffin, and another
was embedded in OCT compound (Miles, Inc., Elkhart, IN),
rapidly frozen in liquid nitrogen, and stored at 70jC.
IHC Analysis to Detect EGF, VEGF, EGFR, VEGFR,
p-EGFR, and p-VEGFR
Paraffin-embedded pancreas from tumor-free normal
mice and pancreatic tumors frommice in all treatment groups
were immunostained to evaluate the expression of EGF,
VEGF, EGFR, and VEGFR. Sections were also stained for
p-EGFR and p-VEGFR.
Determination of PCNA, CD31/PECAM-1 (Endothelial
Cells), and TUNEL
Paraffin-embedded tissues were used to determine
PCNA. Sections were deparaffinized and rehydrated in PBS
as described previously, microwaved for 5 minutes for anti-
gen retrieval, incubated at 4jC with the primary antibody
overnight (mouse IgG2aanti-PCNA), and incubated for 1hour
at room temperature with a secondary antibody (peroxidase-
conjugated rat anti–mouse IgG2a). Frozen tissues used to
identifyCD31/PECAM-1weresectioned (8–10 mm),mounted
on positive-charged slides, and air-dried for 30 minutes.
Frozen sections were fixed in cold acetone (5 minutes), in
acetone/chloroform (vol/vol; 5minutes), and again in acetone
(5 minutes), and washed with PBS. Positive reaction was
visualized by incubating the slides for 10 to 20 minutes with
stable DAB. The positive sections were rinsed with distilled
water, counterstained with Gill’s hematoxylin for 30 seconds,
and mounted with Universal Mount (Research Genetics,
Huntsville AL). Control samples exposed to a secondary
had no specific staining. For the quantification of MVD in
sections stained for CD31, 10 random 0.159-mm2 fields at
100magnificationwere captured for each tumor, andmicro-
vessels were quantified according to the method described
previously [29]. For quantification of PCNA expression, the
number of positive cells was determined in ten 0.159-mm2
fields at 100 magnification.
Analysis of apoptotic cells was performed by using a
commercially available TUNEL kit with the following modifi-
cations: samples were fixed with 4% paraformaldehyde
(methanol free) for 10 minutes at room temperature, washed
twice with PBS for 5 minutes, and then incubated with
0.2% Triton X-100 for 15 minutes at room temperature. After
being washed with PBS, the samples were incubated with
equilibration buffer for 10 minutes at room temperature, and
a reaction buffer was added (containing equilibration buffer,
nucleotide mix, and terminal deoxynucleotidyl transferase
enzyme). Samples were incubated in a humidified chamber
at 37jC for 1 hour in the dark and immersed in 2 SSC for
15 minutes to terminate the reaction. Immunofluorescence
microscopy was performed on an epifluorescence micro-
scope equipped with narrow bandpass excitation filters
mounted in a filter wheel (Ludl Electronic Products, Haw-
thorne, NY). Images were captured by using a chilled,
cooled charge-coupled device camera (Photometrics, Tuc-
son, AZ) and Smart Capture software (Digital Scientific,
Cambridge, UK) on a Macintosh computer. Images were
further processed with Adobe Photoshop software (Adobe
Systems, Mountain View, CA). The total number of apop-
totic cells was quantified by counting 10 randomly selected
microscope fields.
Double Immunofluorescence Staining for CD31/PECAM-1
and EGFR, p-EGFR, VEGFR, p-VEGFR, p-Akt, and TUNEL
(Apoptotic Cells)
Frozen sections of pancreatic tissue from normal mice
and L3.6pl tumors in the pancreas of nude mice were
mounted on slides and fixed. IHC procedures for CD31 assay
were performed as described above. Samples were again
blocked briefly in blocking solution (5% normal horse serum
and 1% normal goat serum in PBS) and incubated overnight
at 4jC with antibody against human EGFR, p-EGFR,
VEGFR, p-VEGFR, or p-Akt. After a wash in PBS, samples
were blocked briefly with blocking solution and incubated
for 1 hour with the streptavidin–Alexa 488 antibody. To visu-
alize nuclei, we briefly incubated the samples with Hoechst
stain. Endothelial cells were identified by red fluorescence,
and EGFR, p-EGFR, VEGFR, p-VEGFR, or p-Akt was iden-
tified by a green fluorescence. The presence of these
growth factor receptors, phosphorylated receptors, or p-Akt in
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endothelial cells was detected by colocalization of red and
green fluorescence, which yields a yellow color. TUNEL-
positive apoptotic cells were detected by localized green
fluorescence within cell nuclei, and endothelial cells were
identified by red fluorescence. Apoptotic endothelial cells were
identified by yellow fluorescence within the nuclei. Quan-
tification of apoptotic endothelial cells was expressed as the
ratio of apoptotic endothelial cells to the total number of
endothelial cells in ten 0.159-mm2 fields at100magnification.
Statistical Analysis
Body weight, the weight of the tumors, PCNA-positive
cells, MVD (CD31/PECAM-1), TUNEL-positive cells, and
ratio of CD31/PECAM-1/TUNEL colocalized cells were com-
pared using the Mann–Whitney U test.
Results
Therapy of Human Pancreatic Cancer in an Orthotopic
Nude Mouse Model by AEE788 or AEE788 Combined
with Gemcitabine
First, we determined the therapeutic efficacy of AEE788,
gemcitabine, or the combination of AEE788 and gemcita-
bine on well-established (visible tumors) human pancreatic
cancer in the pancreas of nude mice. At the end of the study,
treatment with AEE788 alone, gemcitabine alone, or the
combination of AEE788 and gemcitabine did not affect body
weight (Table 1). Mice in the control group had the largest
tumors. Mice treated with gemcitabine had a similar size
(weight) of tumors as the control mice. The tumors in mice
receiving oral AEE788 were nearly 70% smaller than con-
trols. The combination treatment reduced the size of the
tumors by nearly 95% (Table 1). The gross appearance of
a normal pancreas, pancreas from tumor-bearing control-
treated mice, and pancreas from tumor-bearing mice treated
with AEE788 and gemcitabine are shown in Figure 1. The ex-
tensively vascularized tumors in control mice nearly replaced
the entire organ. Tumors frommice treated with AEE788 and
gemcitabine were small and had few blood vessels.
IHC Analysis
Expression of EGF, VEGF, EGFR, and VEGFR was
detected in L3.6pl tumors from all treatment groups. Expres-
sion of p-EGFR and p-VEGFR was found only in tumors from
control and gemcitabine-treated groups and not in tumors
from mice treated with AEE788 or AEE788 plus gemcitabine
(Figure 2). Parenchyma cells or endothelial cells in the nor-
mal pancreas expressed minimal levels of EGF, VEGF,
EGFR, VEGFR, p-EGFR, or p-VEGFR (data not shown).
The double immunofluorescence staining showed that
tumor-associated endothelial cells in the pancreas of all
treatment groups expressed EGFR and VEGFR. Endothelial
cells in tumors from the control treatment group or in the
gemcitabine-treated group, but not from the AEE788 or
AEE788 and gemcitabine-treated tumors, expressed phos-
phorylated EGFR and phosphorylated VEGFR (Figure 3A).
Akt Phosphorylation on Tumor Cells and Tumor-Associated
Endothelial Cells in Normal Nude Mouse Pancreas and
Pancreatic Tumors
Parenchymal cells and vascular endothelial cells in the
normal pancreas expressed minimal levels of phosphory-
lated Akt. In contrast, elevated phosphorylation of Akt was
found in tumor-associated endothelial cells, as well as
tumor cells from the control and gemcitabine-treated mice.
Treatment with AEE788 alone or AEE788 combined with
gemcitabine reduced the expression of p-Akt in both endo-
thelial cells and tumor cells (Figure 3B).
Table 1. Therapy of L3.6pl Human Pancreatic Cancer Cells Growing in the
Pancreas of Nude Mice.
Treatment Body Weight (g) Tumor Incidence Tumor Weight (g)
Median Range Median Range
Control 22.1 18.7–26.6 10/10 1.97 0.8–3.78
Gemcitabine 22.6 19.9–25.6 9/9 1.70 0.27–3.13
AEE788 23.8 22.7–26.5 10/10 0.59* 0.19–1.1
AEE788 +
gemcitabine
23.1 20.6–25.8 10/10 0.11y 0.02–0.25
L3.6p.l cells (1  106) were injected into the pancreas of nude mice. Two
weeks later, treatment began and continued for 5 weeks.
The mice were killed on day 36 of treatment (day 50 of the study) and sub-
jected to necropsy.
Body weight, tumor incidence, and weight were determined.
This is one representative experiment of two.
*P < .05.
yP < .01 vs control.
Figure 1. Gross appearance of a nude mouse normal pancreas and pancreas of mice implanted with L3.6pl human pancreas cancer cells after 5 weeks of
treatment with vehicle (control) or the combination of AEE788 (oral gavage of 50 mg/kg; thrice per week) and gemcitabine (50 mg/kg, i.p.; twice per week).
Arrowheads indicate pancreatic tumor. Note the extensive vascularization of pancreatic tumor in control mice.
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Cell Proliferation, Apoptosis, and MVD
Cell proliferation in the pancreatic tumors was evaluated
by staining for PCNA (Figure 4A). Treatment with AEE788 or
gemcitabine significantly decreased PCNA staining com-
pared to the control group. Treatment with both AEE788
and gemcitabine produced the largest reduction in PCNA
staining (Table 2). ERK1/2 and MAPK signaling level, as
measured by Western blot analysis, was reduced in pancre-
atic cancers from mice treated with AEE788 and AEE788
plus gemcitabine (data not shown).
The induction of apoptosis was evaluated by the TUNEL
method. In tumors from control mice, the mean number of
apoptotic tumor cells was minimal. Treatment with gemcita-
bine or AEE788 increased the number of TUNEL-positive
apoptotic cells. The largest number of apoptotic cells was
found in tumors from mice treated with AEE788 and gemci-
tabine (Table 2).
MVD in the tumor from all treatment groups was deter-
mined subsequent to IHC staining with antibodies against
CD31. Tumors treated with AEE788, gemcitabine, or AEE788
Figure 2. IHC staining for EGF, EGFR, p-EGFR, VEGF, VEGFR, and p-VEGFR. The large L3.6pl tumors were harvested, fixed, and sectioned for histology and
IHC analysis from mice treated with vehicle (control), AEE788, gemcitabine, or the combination of AEE788 and gemcitabine. Sections of tumors from all treatment
groups were stained for expression of EGF, EGFR, p-EGFR, VEGF, VEGFR, and p-VEGFR as described in Materials and Methods section. Tumors from the mice
treated with vehicle or gemcitabine positively stained positive for p-EGFR and p-VEGFR. Treatment with AEE788 alone, or AEE788 and gemcitabine significantly
decreased the phosphorylation of EGFR and VEGFR.
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and gemcitabine had a significantly lower MVD than con-
trols. The largest decrease in MVD occurred in tumors
from mice treated with the combination of AEE788 and
gemcitabine (Table 2).
Figure 3. (A) Double immunofluorescence staining for CD31/PECAM-1 and EGFR, p-EGFR, VEGFR, and p-VEGFR in pancreatic tumors. Samples were stained
with anti –CD31/PECAM1 antibody (red fluorescence) and anti –EGFR, p-EGFR, VEGFR, or p-VEGFR antibody in green fluorescence as described in Materials
and Methods section. Colocalization of CD31 and EGFR, p-EGFR, VEGFR, and p-VEGFR yields a yellow fluorescence. Expression of EGFR and VEGFR by
tumor-associated endothelial cells was found in tumors from all treatment groups. Phosphorylated EGFR and VEGFR on endothelial cells were decreased by
treatment with AEE788 or AEE788 and gemcitabine. (B) Double immunofluorescence staining for CD31/PECAM-1 and p-Akt in normal mouse pancreas and
pancreatic tumor of nude mice treated with control, gemcitabine, AEE788, or AEE788 plus gemcitabine. CD31/PECAM-1 was stained with red fluorescence and
p-Akt was stained with green fluorescence. Yellow fluorescence indicates expression of phosphorylated Akt on tumor-associated endothelial cells.
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Immunofluorescence Double Staining for CD31/PECAM-1
and TUNEL
Finally, we examined whether treatment with AEE788
and/or gemcitabine would produce significant apoptosis of
endothelial cells. In control tumors, the CD31/TUNEL fluo-
rescent double-labeling technique (colocalization) revealed a
median of 0% apoptotic endothelial cells, whereas treatment
with AEE788 and gemcitabine produced a median of 9%
(range, 0–16%) apoptotic endothelial cells (Table 2). Apop-
totic tumor–associated endothelial cells as well as tumor
cells in mice treated with both AEE788 and gemcitabine are
shown in Figure 4B.
Discussion
The level of expression of EGF, EGFR, VEGF, and VEGFR
has been reported to correlate with the progressive growth
and metastasis of cancer, its resistance to chemotherapy,
and hence the poor survival of patients [5,8,20–22]. The
rapid growth and spread of the human L3.6pl pancre-
atic cancer cells implanted into the pancreas of nude mice
also correlated with the expression of EGF, VEGF, their
receptors, and the phosphorylated receptors. Parenchymal
cells and endothelial cells in a normal pancreas expressed
minimal levels of ligands and receptors. In contrast, tumor-
associated endothelial cells expressed elevated levels of
EGFR and VEGFR, which were phosphorylated, suggesting
that ligands released by tumor cells upregulate the expres-
sion of their receptors on tumor-associated endothelial cells
in a paracrine manner.
Figure 4. (A) Analysis of cell proliferation (PCNA), MVD (endothelial cells), and apoptosis (TUNEL) in L3.6pl cells growing in the pancreas of nude mice. Mice were
treated with vehicle (control), AEE788, gemcitabine, or the combination of AEE788 and gemcitabine. (B) Double immunofluorescence staining of CD31/PECAM-1
and TUNEL in pancreatic tumors from mice treated with the combination of AEE788 and gemcitabine. Endothelial cells (CD31+) stained red fluorescence and
apoptotic cells (TUNEL+) stained green fluorescence. Colocalization of endothelial cells undergoing apoptosis yields yellow fluorescence.
Table 2. IHC Analysis of L3.6pl Human Pancreatic Cancer Cells Growing in
the Pancreas of Nude Mice.
Treatment Group Tumor Cells Endothelial Cells
PCNA* TUNEL* CD31* TUNEL+ (%)y
Mean Range
Control 488 ± 59 1 ± 1 55 ± 12 0 0–0
Gemcitabine 414 ± 49z 9 ± 3z 31 ± 12z 1 0–3
AEE788 272 ± 52§ 15 ± 5§ 26 ± 5§ 3 0–7
AEE788 + gemcitabine 212 ± 51§ 23 ± 6§ 16 ± 6§ 9 0–16§
*Mean ± S.D. positive cells per field determined from measurement of 10
random 0.159-mm2 fields at 100 magnification.
yPercentage of CD31/TUNEL+ cells in 10 random 0.011-mm2 fields at 400
magnification.
zP < .01 vs control.
§P < .001 vs control.
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EGF and VEGF are also known to be survival factors ren-
dering cells more resistant to apoptosis and chemotherapy
by activation of Akt, which regulates antiapoptotic mecha-
nisms by activating NF-nB and inactivating the proapoptotic
protein, BAD, and others [10,30–32]. We could find minimal
phosphorylation of Akt in vascular endothelial cells or pancre-
atic parenchyma cells in the normal pancreas. In contrast, we
found an intense phosphorylation of Akt on tumor-associated
endothelial cells and pancreatic tumor cells in untreated mice
or mice treated with gemcitabine. This phosphorylation of Akt
was inhibited by treatment with AEE788 alone or AEE788
plus gemcitabine. These data indicate that EGF and VEGF
released by tumor cells can phosphorylate Akt on tumor-
associated endothelial cells in a paracrine manner and on
tumor cells in an autocrine manner.
We found that L3.6pl cells were relatively resistant to
gemcitabine treatment (Table 1); however, when combined
with AEE788, gemcitabine reduced tumor growth by nearly
95%. The result that combination treatment was most
effective on the relative gemcitabine-resistant tumor cells
suggests that the primary target of treatment could be the
tumor-associated endothelial cells rather than the tumor
cells. The apoptosis of tumor-associated endothelial cells
leads to hypoxia, resulting in decreased tumor cell prolifer-
ation and increased apoptosis of tumor cells.
The abrogation of Akt phosphorylation by AEE788 in
tumor-associated endothelial cells and tumor cells would
render these cells highly sensitive to chemotherapy because
of loss of antiapoptotic mechanism. Endothelial cells in tumors
undergo cell proliferation more frequently than those in
normal tissues [33] and, therefore, the tumor-associated
endothelial cells should be more attractive targets for chemo-
therapeutic reagents. Indeed, treatment with AEE788 and
gemcitabine produced the highest incidence of apoptosis in
tumor cells and tumor-associated endothelial cells, resulting
in the lowest MVD and proliferating cells compared to either
agent alone.
Another reason that combination treatment overcomes a
low efficacy of gemcitabine is that combination treatment
would improve the drug delivery of the gemcitabine into the
tumor cells by inhibiting VEGFR signaling. Increased vascu-
lar permeability is a major cause of interstitial hypertension
responsible for reduction in the delivery of molecules to tumor
cells [34,35]. Indeed, the use of an anti–VEGFR monoclonal
antibody has been shown to lower vascular permeability and
reduce vascular resistance by normalization of vascular
architecture and function [34]. Whether AEE788 can also
lower interstitial hypertension and increase uptake of gemci-
tabine by cancer cells is under current investigation.
Published work from our laboratory demonstrated that
either EGFR inhibition or VEGFR phosphorylation, com-
bined with gemcitabine, produced therapy of human pancre-
atic carcinoma in nude mice [26,36]. The current data using
a dual tyrosine kinase inhibitor of EGFR and VEGFR can-
not distinguish between these signaling pathways. Using a
chemotherapy-resistant human ovarian cancer implanted
in nude mice, we found that AEE788 had longer-lasting in-
hibition of EGFR phosphorylation compared to VEGFR
phosphorylation (manuscript submitted for publication), sug-
gesting that inhibition of the EGFR signaling may be the
dominant mechanism leading to induction of apoptosis in
tumor-associated cells and, hence, tumor cells.
In conclusion, because both EGFR and VEGFR signal-
ings in tumor cells and tumor-associated endothelial cells
regulate the progressive growth of pancreatic cancer, the
ability to abrogate their activation, and hence their signaling
pathways, markedly decreased tumor cell proliferation and
induced apoptosis in tumor cells and tumor-associated endo-
thelial cells. The success in using a dual tyrosine kinase in-
hibitor with the conventional chemotherapeutic gemcitabine
holds promise for the therapy of human pancreatic cancer.
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